Barbara Burtness, MD
Immunotherapy continues to advance the care of patients with head and neck cancer, with researchers now exploring combining these therapies together, as well as adding immunotherapy to standard approaches, explains Barbara A. Burtness, MD.
In an interview with OncLive, Burtness, a professor of medicine at Yale Cancer Center, discussed the current role of immunotherapy in head and neck cancer and potential combination regimens on the horizon.
OncLive: What is the current role of immunotherapy in head and neck cancer?
Immunotherapy has made a change in the management of patients with metastatic and recurrent head and neck cancer. For patients who have been previously exposed to platinum therapy, either nivolumab or pembrolizumab (Keytruda) has been shown to be an appropriate drug that leads to responses—some of which are durable responses.
... to read the full story